Since SRC‐1 can also activate Wnt/β‐catenin, Hedgehog, and HIF1 signaling pathways, targeting SRC‐1 by bufalin treatment may enhance the sensitivity of CRC to PD‐L1 antibody treatment by inhibiting these oncogenic pathways, too. The gene discussed is SRC; the disease is colorectal carcinoma.